Bayer: successful trial in prostate cancer
Safety analyses indicate that darolutamide + ADT is comparable to placebo + ADT, confirming its well-established tolerability profile observed in previous trials.
Bayer plans to present the detailed results at a forthcoming scientific conference, and to seek global regulatory approval to extend darolutamide's indication.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction